Generated: April 29, 2017
Which drugs does patent 7,067,555 protect, and when does it expire?
|Title:||Sertraline oral concentrate|
|Abstract:||The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalena- mine methanesulfonate.|
|Inventor(s):||Harper; Nancy J. (Groton, CT), Ranade; Gautam R. (East Lyme, CT), Welch; Willard M. (Mystic, CT)|
|Assignee:||Pfizer Inc (New York, NY)|
Patent Claim Types:|
see list of patent claims
|Composition; Formulation; Dosage form; Compound; Use;|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Patented / Exclusive Use|
|CONCENTRATE;ORAL||020990-001||Dec 7, 1999||AA||RX||Yes||Yes||7,067,555*PED||► Subscribe||Y|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
Export unavailable in trial.
Subscribe for complete access.